New vaccine strategy aims to outsmart drug-resistant ovarian cancer
NCT ID NCT05479045
First seen Mar 22, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tests whether adding a cancer vaccine (NY-ESO-1) to standard immunotherapy can prevent the cancer from becoming resistant in people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. About 24 women with stage III or IV ovarian cancer will receive the combination. The goal is to see if this approach can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.